Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
Stability Seekers: 7 Low-Volatility Stocks for Uncertain Times
04:02pm, Thursday, 23'rd Nov 2023
At first blush, focusing on low-volatility stocks may appear an overly pessimistic strategy. After all, the benchmark S&P 500 gained almost 8% in the trailing month.
Merck Will Keep Your Retirement Income Healthy
02:38am, Thursday, 23'rd Nov 2023
Merck is a legacy drugmaker with a history of fat margins and occasional robust growth. The company is entering a new growth phase, making it a good investment opportunity. Merck has a low forward P/E
Merck (MRK) to Acquire Private Neuroscience Company for $610M
10:31am, Wednesday, 22'nd Nov 2023
Merck (MRK) has been a shareholder in Caraway Therapeutics since 2018 through its MRL Ventures Fund.
Merck: A Dividend Growth Stock Worth Considering
04:31am, Tuesday, 21'st Nov 2023
Merck reported positive quarterly earnings with 6.7% year-over-year revenue growth and improved operating margin. The company generated strong leveraged free cash flow and reduced financial leverage,
US FDA panel votes against Merck's chronic cough drug
04:18pm, Friday, 17'th Nov 2023
The U.S. health regulator's advisers on Friday did not recommend Merck's drug for the treatment of chronic cough.
Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer
12:48pm, Friday, 17'th Nov 2023
Following this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers. Overall, the drug is approved for 38 indications in the country.
Merck's Keytruda combo wins FDA approval for gastric cancer
10:17am, Friday, 17'th Nov 2023
Merck & Co Inc (NYSE:MRK) announced on Thursday that its anti-PD-1 therapy Keytruda in combination with chemotherapy has been approved by the U.S. Food and Drug Administration (FDA) for gastric cancer
Merck's Keytruda gets approval to treat certain types of gastric cancer
05:52pm, Thursday, 16'th Nov 2023
Merck MRK, +0.63% said late Thursday that the Food and Drug Administration has approved its star cancer drug Keytruda as treatment for some adult gastrointestinal cancers, alongside chemotherapy. Appr
US FDA staff flags concerns on Merck's chronic cough drug
12:32pm, Wednesday, 15'th Nov 2023
U.S. Food and Drug Administration's reviewers on Wednesday flagged concerns that data on Merck's chronic cough drug might not be sufficient to prove meaningful benefit, according to documents released
2 Healthcare Stocks That Could Make You Richer
09:37am, Wednesday, 15'th Nov 2023
Merck has the tools to manage a major patent cliff that is coming in the next few years. Intuitive Surgical's leadership in its field and growth avenues make it a strong buy.
At $100 Does Merck Stock Have Room For Growth?
09:00am, Tuesday, 14'th Nov 2023
Merck (NYSE: MRK) reported its Q3 results last month, with revenues and earnings beating the street estimates, and we believe that MRK stock has ample room for growth,
The 3 Best Defensive Stocks for Uncertain Times
07:12pm, Monday, 13'th Nov 2023
Investment is not just the art of finding potential multi-bagger stocks. There is a lot of thinking and strategizing involved in creating a portfolio that beats the index, delivers regular cash flows,
Nike, Merck Among 13 Companies To Announce Annual Dividend Increases In Second Half Of November
10:12am, Monday, 13'th Nov 2023
Investors were rewarded with 10%+ dividend increases from Snap-on Tools and ADP in the first half of November. Other companies that rewarded investors in the first two weeks of the month were Emerson,
3 S&P stocks with growth to weather a downturn
08:16am, Monday, 13'th Nov 2023
If you're looking for companies with steady profitability, cash flow and dividends, then Broadcom Inc. NASDAQ: AVGO, McCormick & Co. Inc. NYSE: MKC and Merck & Co. NYSE: MRK are worthy candidates.
5 Dirt-Cheap Healthcare Stocks With Big Dividends To Buy Now
01:10pm, Saturday, 11'th Nov 2023
While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and li
